GSK Tykerb Opportunities Exist In Early Breast Cancer Setting – Oncologist
This article was originally published in The Pink Sheet Daily
Executive Summary
As many as 10 percent of early-stage HER2 positive breast cancer patients, who are not ideal candidates for Herceptin, could be candidates for Tykerb, oncologist Ellis estimates.